Adolescent BCG Revaccination Induces a Phenotypic Shift in CD4 T Cell Responses to Mycobacterium Tuberculosis
Overview
Authors
Affiliations
A recent clinical trial demonstrated that Bacille Calmette-Guérin (BCG) revaccination of adolescents reduced the risk of sustained infection with Mycobacterium tuberculosis (M.tb). In a companion phase 1b trial, HVTN 602/Aeras A-042, we characterize in-depth the cellular responses to BCG revaccination or to a H4:IC31 vaccine boost to identify T cell subsets that could be responsible for the protection observed. High-dimensional clustering analysis of cells profiled using a 26-color flow cytometric panel show marked increases in five effector memory CD4 T cell subpopulations (T) after BCG revaccination, two of which are highly polyfunctional. CITE-Seq single-cell analysis shows that the activated subsets include an abundant cluster of Th1 cells with migratory potential. Additionally, a small cluster of Th17 T cells induced by BCG revaccination expresses high levels of CD103; these may represent recirculating tissue-resident memory cells that could provide pulmonary immune protection. Together, these results identify unique populations of CD4 T cells with potential to be immune correlates of protection conferred by BCG revaccination.
Tuberculosis vaccines and therapeutic drug: challenges and future directions.
An Y, Ni R, Zhuang L, Yang L, Ye Z, Li L Mol Biomed. 2025; 6(1):4.
PMID: 39841361 PMC: 11754781. DOI: 10.1186/s43556-024-00243-6.
Dintwe O, Ballweber Fleming L, Voillet V, McNevin J, Seese A, Naidoo A Nat Commun. 2024; 15(1):5191.
PMID: 38890283 PMC: 11189459. DOI: 10.1038/s41467-024-49050-1.